| Time | Nov.17-19, 2026 |
| Location | Lisbon, Portugal |
| Company | DIMA BIOTECH |
| Booth | #149 |
| Time | Nov.17-19, 2026 |
| Location | Lisbon, Portugal |
| Company | DIMA BIOTECH |
| Booth | #149 |
DIMA BIOTECH (hereafter referred to as “DIMA”) is pleased to announce its participation in Protein & Antibody Engineering Summit Europe 2026 (PEGS Europe 2026), where we will showcase the latest advancements in Nanodisc technology platforms, multi-pass transmembrane protein research tools, and therapeutic monoclonal antibody development.
PEGS Europe 2026 is a premier conference focused on protein engineering, antibody discovery, and next-generation biologics development. Taking place on November 16–19, 2026, in Lisbon, Portugal, the summit brings together global scientists and industry leaders to discuss advances in biologic therapeutics.
The conference program covers key areas including antibody engineering, multispecific antibodies, protein design, next-generation conjugates, immunoengineering, oncology, and AI-driven biologics development, with dedicated sessions on challenging targets and innovative discovery technologies. As biologics research advances toward increasingly complex targets and molecular formats, technologies enabling functional protein production, screening, and antibody discovery are becoming essential. PEGS Europe 2026 provides an important platform for exploring emerging solutions and fostering collaboration across the global biologics community.
DIMA will participate in PEGS 2026 through both a scientific presentation and an exhibition booth. As part of the featured session “Antibodies Against Membrane Protein Targets,” DIMA will present its work on applying Nanodisc technology platforms to therapeutic antibody discovery against multi-pass transmembrane protein targets, highlighting strategies to address some of the key challenges associated with complex membrane proteins. Visitors are also welcome to meet our team at Booth #149 to learn more about our membrane protein platforms, antibody discovery capabilities, and solutions for challenging drug targets.
We are proud to share that our CEO, Dr. Donghui Ma, will be speaking on Thursday 19 November at 9:45 a.m, sharing the application of Nanodisc technology platforms to develop therapeutic mAbs for multi-pass transmembrane protein targets.
Many important druggable targets are multi-pass transmembrane proteins. The key challenge is the extreme difficulty in obtaining purified functional proteins. To develop therapeutic lead mAbs on these targets, DIMA has optimized every step of antibody discovery process. In this poster presentation, we will exhibit how we integrate DIMA’s Nanodisc technologies, including SyndiscTM, PeptiNanodiscTM, Single B enrichment and DiLibraryTM Mammalian display technology platforms to develop mAbs against a challenge multi-pass transmembrane target, CLDN18.2.
Join Our Presentation At a specific track: Antibodies Against Membrane Protein Targets
DIMA will participate in PEGS Europe 2026 through an exhibition booth and a scientific poster presentation. Visit us at Booth #149 to explore our integrated research platform for drug discovery, including our Nanodisc Membrane Protein Platforms and Ready-to-Test Lead mAbs, designed to support antibody discovery and development against challenging targets.
The location of DIMA BIOTECH’s exhibition booth
Come learn more about our studies and connect with us at booth #149. We look forward to meeting you there!
Schedule a meeting with Us!
Complete the form to receive exclusive offers.